Sellas Life Sciences (SLS) 0.93% Drop – SLS009 Might Be the Hidden Gem! скачать в хорошем качестве

Sellas Life Sciences (SLS) 0.93% Drop – SLS009 Might Be the Hidden Gem!

‪@WallStreetPulse01‬ Sellas Life Sciences (SLS) $2.14 , 0.93% Drop – SLS009 Might Be the Hidden Gem! Sellas Life Sciences Group (SLS) closed Friday, October 17, 2025, at $2.14, down 0.93% on over 8 million shares traded, more than three times its daily average. In this video, we cover: • Friday’s high-volume 0.93% dip 📉 • Why the market is ignoring SLS009 Phase 2 success while focusing only on the Phase 3 REGAL trial for GPS 💊 • Institutional positioning: BlackRock, Morgan Stanley, Marshall Wace accumulating SLS 🏦 • Financial runway and recent capital raises 💰 • SLS’s dual-asset pipeline: GPS (Galinpepimut-S) & SLS009 (tambiciclib) ⚡ • Bull vs Bear scenarios: REGAL trial outcomes vs SLS009 as an undervalued buffer 🔥 • Key catalysts: R&D Day (Oct 29) & REGAL trial data 📊 This is a high-risk, high-reward biotech stock that requires active research. Platforms like Fidelity, Interactive Brokers, and SoFi Invest provide access, but understanding the clinical data is critical. 📌 Disclaimer: This video is for educational purposes only. Not financial advice. Always DYOR (Do Your Own Research). 👍 Like, Comment, and Share to help other investors understand SLS! #SellasLifeSciences #SLSStock #BiotechStocks #Investing #StockMarket #Robinhood #Fidelity #SoFiInvest #Phase3Trial #SLS009 #GPS #AML #StockAnalysis Sellas Life Sciences, SLS stock, SLS stock analysis, SLS stock today, SLS price, SLS news, SLS forecast, SLS prediction, SLS clinical trials, SLS GPS, SLS REGAL trial, SLS AML, SLS009, SLS dual pipeline, SLS biotech, SLS Phase 2, SLS Phase 3, SLS trial data, SLS stock catalysts, SLS institutional ownership, SLS BlackRock, SLS Morgan Stanley, SLS Marshall Wace, SLS stock volume, SLS high volume, SLS price action, SLS biotech investment, SLS risk reward, SLS investment strategy, SLS online investing, SLS Robinhood, SLS SoFi Invest, SLS Fidelity, SLS Interactive Brokers, SLS intelligent portfolio, SLS self investing, SLS financial runway, SLS capital raise, SLS dilution risk, SLS investor positioning, SLS stock opportunity, SLS undervalued, SLS hidden gem, SLS dual asset story, SLS pipeline value, SLS drug candidates, SLS AML treatment, SLS cancer immunotherapy, SLS vaccine, SLS small molecule inhibitor, SLS tambiciclib, SLS clinical data, SLS R&D day, SLS earnings, SLS future catalysts, SLS stock volatility, SLS high-risk biotech, SLS institutional accumulation, SLS retail investors, SLS market expectation, SLS stock mispricing, SLS upside potential, SLS downside risk, SLS stock strategy, SLS individual brokerage, SLS research required, SLS Phase 2 success, SLS REGAL data, SLS share price, SLS market narrative, SLS investor insights, SLS biotech opportunity, SLS speculative stock, SLS stock review, SLS investment help, SLS stock forecast 2025, SLS clinical trial results, SLS revenue potential, SLS biotech news, SLS pharma investment, SLS US stocks, SLS top biotech, SLS portfolio strategy, SLS stock update, SLS trading alert, SLS stock prediction, SLS SEC filings, SLS investment analysis, SLS research-based investing, SLS oncology stock, SLS AML therapy, SLS biotech pipeline.